Meister Keith A. sold $107.0M of ILMN (indirect holdings)

Meister Keith A. sold 669,596 indirectly-held shares of ILLUMINA, INC. (ILMN) at an average of $159.86 ($147.50–$165.50, $107.04M total) across 17 trades over 2026-05-28 to 2026-06-01.

Original reporting
SEC EDGAR · Meister Keith A.
Published Jun 1, 2026, 10:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 28, 2026, 3:42 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ILMN
Bearish
medium confidence
Mentioned
$ILMN
Relevance
8/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ILMNBearishLow
01

Why it matters

The $107M sale by a director is a material insider transaction that can influence short‑term price dynamics.

02

Market read

Large insider sell creates potential downside pressure for Illumina; traders may watch for price reaction.

03

What to watch

Potential upcoming FDA decisions or pipeline news could offset the negative signal from the insider sell.

Relevance 8/10Novelty 8/10Timing: after filing today

Background

SEC Form 4 filing discloses insider transactions; this is the first public report of the sale.

Company-level read

Ticker impact

$ILMNBearishMedium confidence
Context

Director Keith A. Meister sold 669,596 shares of Illumina for $107M, reducing his holdings to 2.83M shares.

Expected impact

likely pressure as the market prices in the $107M insider sell

Evidence & confidence

The sale size is material for a mid‑cap biotech and the insider is a director; such transactions often lead to short‑term sell‑offs.

Market effects

May raise concerns for other biotech stocks as investors watch insider activity for sentiment cues.

Limited to U.S. markets where Illumina trades; no broader regional effect.

Minimal global impact beyond Illumina's shareholder base.

Counterpoint

The sale could be a routine liquidity event unrelated to company fundamentals; price may remain stable.

Key entities

  • Illumina, Inc.

    US‑listed biotech company (ticker ILMN) whose director sold shares.

  • Meister Keith A.

    Director of Illumina who executed the sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ILMNMed

Illumina selected to help bring precision medicine into everyday healthcare in Singapore

Illumina (ILMN) was selected for the SG-INSIGHT study, part of Singapore's National Precision Medicine program, to provide whole-genome sequencing for 450,000 residents. The study aims to integrate genomic data with healthcare to tailor treatments. Illumina will operate through its local facility, complying with Singapore's regulations. This follows their support in the previous phase of the program.

$ILMNHighAI 9/10

What Sent Illumina Stock Lower?

Illumina (ILMN) stock dropped 18.6% on October 30, 2026, despite beating earnings estimates and raising its full-year revenue outlook. The decline followed a mixed Q3 report where revenue missed estimates due to tariff refunds. Management cited strong sequencing consumables sales and NovaSeq X instrument placements. The broader market also fell, with AI-related stocks underperforming.

$ILMNHighAI 8/10

[Illumina Q3 2026 Earnings Call] Illumina Raises Full-Year Guidance to $4.64–$4.66 Billion as NovaSeq X Placements Top 80 and EPS Hits $1.44

Illumina reported Q3 2026 revenue of $1.17B, up 4.7% YoY, and EPS of $1.44. The company raised full-year guidance to $4.64–$4.66B, citing strong clinical demand and NovaSeq X placements. Operating margin was 25%, 100 bps ahead of guidance. Illumina expects 4.5% organic growth in Q4 and high-single-digit growth for 2027.